Patients, plans weigh tradeoffs between lower premiums, fewer doctors.
Under pressure to control costs in a rapidly changing and uncertain healthcare market, insurers are slimming down provider networks in plans offered through federal and state exchanges and by Medicare Advantage (MA) plans. Similarly, plans and pharmacy benefit managers are establishing “preferred” pharmacy networks to control outlays on prescription drugs.
Doctors and hospitals have been fighting back, claiming that patients will lose choice and access to quality care. Officials in Maine and New Hampshire went after Anthem Blue Cross Blue Shield last fall for marketing exchange plans that excluded certain state hospitals. In Washington state, several insurers were kept off the exchange initially due to “inadequate” provider networks. Similar issues emerged in South Dakota, Pennsylvania and Mississippi, where legislators cited “any willing provider” laws requiring insurers to include any provider that accepts its terms.
Cuts in providers covered by MA plans have also drawn protests and legal action. Physicians in Connecticut filed suit in December to block UnitedHealthCare from dropping more than 2,000 doctors from its MA plan in that state. State medical societies in Ohio, New York and Florida weighed similar action against plans moving to cancel or change contracts with doctors and hospitals. The network changes in Connecticut drew attention on Capitol Hill, prompting a Senate hearing and proposals to require notice in advance of the annual MA open enrollment period of provider network changes.
Insurers say that slimmer networks are a way to maintain low premiums and copays in the face of major reductions in MA rates. Private Medicare plans have to meet clear “network adequacy” standards, they emphasize, noting that their aim is to establish “high value” and “high performing” provider networks that offer quality care.
Many consumers and payers accept the trade of limits on provider access for lower premiums. A December poll of small employers found the majority willing to offer plans with narrow networks if that means reduced costs.
Anxious to avoid “sticker shock” when consumers began shopping for coverage, the Obama administration approved many lower-cost Bronze plans with more limited provider rolls. As Qualified Health Plans can’t exclude less healthy individuals and must offer minimum essential benefits, a way to keep a lid on premiums, deductibles and copays is to establish narrow or “ultra-narrow” networks.
Former HHS Secretary Mike Leavitt explained in a recent interview with Kaiser Health News that some consumers prefer to have fewer choices in providers and to assume added risk if that means lower premiums. While the tradeoff is not good for everyone, Leavitt emphasizes that “you can’t constrain costs” unless insurers have the ability to narrow networks over time. “If you require everyone to have everything, then costs will continue to go up.”
Steering beneficiaries to restricted networks is nothing new. Kaiser Permanente has long had a limited cadre of doctors and hospitals employed by the Kaiser system, and perennially earns high marks for quality and access.
Ironically, Congressional Republicans, who otherwise might agree with Leavitt’s argument, seized on provider curbs as another opportunity to attack President Obama for promising Americans that his program would let them keep their doctors, as well as their current plans.
The idea that plans can save money by managing networks more tightly is supported by greater transparency in hospital and provider rates that reveal huge differences in charges for common procedures-with little correlation to quality.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More